To address these knowledge gaps, Song et al., evaluated the therapeutic efficacy of NPs in models with variable TME and tumor types by using genomically-validated and engineered mouse models of basal-like (C3(1)/SV40 T/t-antigen) and claudin-low [T11/TP53/(T11)] mammary tumors 44. The gene discussed is TP53; the disease is neoplasm.